Literature DB >> 8632682

Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes.

M Karasawa1, K Okamoto, T Maehara, N Tsukamoto, K Morita, T Naruse, M Omine.   

Abstract

Double minute chromosomes (dmin) are relatively rare in leukemias. Cytogenetic analysis of blood cells from a woman with blastic phase chronic myelogenous leukemia (BC-CML) showed numerous dmin chromosomes and complex abnormalities including a Philadelphia (ph(1))-chromosome. Oncogene amplification in hematopoietic malignancies is also rare. Using PCR, we retrospectively investigated the extent of c-myc gene amplification in DNA extracted from stored blood smears from the patient. To qualify the PCR products, the beta-globin gene was used as the internal reference gene and it was co-amplified with the c-myc gene. The extent of amplified c-myc was about 6.8-fold. This finding suggests that the c-myc gene was amplified in dmin and that the gene amplification contributes to the progression to acute leukemia or rapid growth of leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8632682     DOI: 10.1016/0145-2126(95)00125-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

2.  Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.

Authors:  Hui Li; Zhenglan Huang; Miao Gao; Ningshu Huang; Zhenhong Luo; Huawei Shen; Xin Wang; Teng Wang; Jing Hu; Wenli Feng
Journal:  J Exp Clin Cancer Res       Date:  2016-09-06

3.  Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.

Authors:  Jonathan W Kotula; Jinpeng Sun; Margie Li; Elizabeth D Pratico; Mark P Fereshteh; Douglas P Ahrens; Bruce A Sullenger; Jeffrey J Kovacs
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.